Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101

Journal of Clinical Oncology

Volumn 25, Issue 21, 2007, Pages 3055-3060

  Miller, Antonius A ^a   Murry, Daryl J ^a   Owzar, Kouros ^a   Hollis, Donna R ^a   Lewis, Lionel D ^a   Kindler, Hedy L ^a   Marshall, John L ^a   Villalona Calero, Miguel A ^a   Edelman, Martin J ^a   Hohl, Raymond J ^a   Lichtman, Stuart M ^a   Ratain, Mark J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; PLACEBO;

ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMOGLOBINOPATHY; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE DRUG DOSE; SMOKING; SOLID TUMOR; TOXICITY TESTING;

ADMINISTRATION, ORAL; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PROBABILITY; QUINAZOLINES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34547701893     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.6210     Document Type: Article

References (21)

1. Baselga J, Artega CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23:2445-2459, 2005
2. Artega C: Targeting HER1/EGFR: A molecular approach to cancer therapy. Semin Oncol 30:3-14, 2003 (suppl 7)
3. Hidalgo M, Siu LL, Nemunaitis J, et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279, 2001
4. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
5. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. J Clin Oncol 23:1s, 2005 (suppl 16s; abstr 1)
6. Pugh RH, Murray-Lyon IM, Dawson JL, et al: Transection of the esophagus for bleeding esophageal varices. Br J Surg 60:646-649, 1973
7. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
8. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
9. Tukey JW: Exploratory Data Analysis. Reading, MA, Addison-Wesley Publishing Co Inc, 1977
10. Hajek J, Sidak Z, Sen PK: Theory of Rank Tests (ed 2). San Diego, CA, Academic Press, 1999
11. R Development Core Team: R: A Language and Environment for Statistical Computing. Vienna, Austria, R Foundation for Statistical Computing, 2006
12. Hothorn T, Hornik K, van de Wiel MA, et al: A lego system for conditional inference. Am Stat 60:257-263, 2006
13. Ling J, Johnson KA, Miao Z, et al: Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos 34:420-426, 2006
14. Lu JF, Eppler SM, Wolf J, et al: Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 80:136-145, 2006
15. Perez-Soler R, Chachoua A, Hammond LA, et al: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238-3247, 2004
16. Venook AP, Egorin MJ, Rosner GL, et al: Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 18:2780-2787, 2000
17. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987
18. Hamilton M, Wolf JL, Rusk J, et al: Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 12:2166-2171, 2006
19. Venook AP, Egorin MJ, Rosner GL, et al: Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 16:1811-1819, 1998
20. Venook AP, Enders Klein C, Fleming G, et al: A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol 14:1783-1790, 2003
21. Ratain MJ, Miller AA, McLeod HL, et al: The Cancer and Leukemia Group B Pharmacology and Experimental Therapeutics Committee: A historical perspective. Clin Cancer Res 12:3612s-3615s, 2006 (supp 11)